Lab-developed tests look likely to be removed from FDA oversight. That has to change, writes Walter G. Johnson.

Oncology Focus : CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and hematological malignancies. Significant attention on gastrointestinal tract and ...

Researchers optimized healthcare AI for diagnoses, analyzed gender bias in image searches and found tiny DNA circles that ...

Infection research stands at the forefront of global health initiatives, particularly considering emerging pathogens and antimicrobial resistance. The quest for effective interventions necessitates ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a new editorial.

The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by Viatris an ...

Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

Analyst Jack Allen from Robert W. Baird maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) and keeping the ...